Compare Eli Lilly And Co (LLY) vs Nokia Corp (NOK) Price & Performance

Eli Lilly (LLY) trades at $1,150.86, down 2.39% on the day, with a bullish technical signal from moving averages and strong fundamental performance. The company reported robust earnings beats in recent quarters, with Q1 2026 EPS of $8.55 exceeding expectations by 23%. Revenue surged to $65.18 billion in 2025, driving a net income margin of 34.99%. Recent news highlights LLY's $2.8 billion acquisition of AtaiBeckley to expand its neuroscience pipeline, signaling strategic growth in mental health treatments.

Outlook remains positive with analyst consensus price target of $1,380 implying 20% upside, supported by 73% buy ratings. Key risks include high valuation multiples (P/E 41.89) and rising debt levels, though operating cash flow growth to $16.81 billion in 2025 provides financial flexibility. Investors should monitor Q2 2026 earnings on August 5 for continued execution on weight-loss drug demand and integration of recent acquisitions.

Nokia (NOK) trades at $10.115, down 0.05% on the day, with a bearish technical signal from moving averages but bullish oscillators. The company reported mixed Q1 2026 earnings, missing EPS estimates, but has beaten expectations in prior quarters. Revenue for 2025 was $19.89B with a net income margin of 3.98%, while the P/E ratio stands at 63.48, indicating a premium valuation. Recent news highlights Nokia's strategic pivot to AI-powered networking, including partnerships with Nvidia and telecom providers.

The outlook for NOK is cautiously optimistic, driven by AI and 5G demand, but high valuation and recent earnings miss pose risks. Analyst consensus is a Buy with a $18.00 price target, suggesting significant upside. Key risks include execution on AI initiatives, competitive pressures, and supply chain constraints. The stock's performance hinges on delivering sustained growth from its AI infrastructure investments.